{"id":3191,"date":"2024-08-30T06:24:07","date_gmt":"2024-08-30T06:24:07","guid":{"rendered":"https:\/\/lightox.co.uk\/?page_id=3191"},"modified":"2024-10-16T13:34:39","modified_gmt":"2024-10-16T13:34:39","slug":"wound-care","status":"publish","type":"page","link":"https:\/\/lightox.co.uk\/wound-care\/","title":{"rendered":"Wound Care"},"content":{"rendered":"
[vc_row thb_full_width=”true” thb_row_padding=”true” thb_column_padding=”true” content_placement=”middle” parallax=”content-moving” parallax_speed_bg=”1.6″ el_class=”top-row” css=”.vc_custom_1724997681211{padding-bottom: 10vh !important;background-image: url(https:\/\/lightox.co.uk\/wp-content\/uploads\/2024\/08\/MRSA_back.jpg?id=3192) !important;background-position: center;background-repeat: no-repeat !important;background-size: cover !important;}” el_id=”header” bg_gradient1=”rgba(50,0,130,0.35)” bg_gradient2=”rgba(50,0,130,0.45)”][vc_column thb_color=”thb-light-column” offset=”vc_col-lg-11″][vc_empty_space mobile_height=”7vh” height=”12vh”][vc_row_inner][vc_column_inner thb_color=”thb-light-column” width=”1\/4″ css=”.vc_custom_1578433242029{padding-right: 3vw !important;}”][\/vc_column_inner][vc_column_inner thb_color=”thb-light-column” width=”3\/4″ css=”.vc_custom_1578594891004{padding-top: 8vh !important;}”][vc_column_text css=”” animation=”animation bottom-to-top”]\n
\n
THERAPEUTICS\u00a0 <\/span>\u00a0I\u00a0\u00a0 LXD231<\/h6>\n<\/div>\n[\/vc_column_text][vc_column_text css=””]\n

We are developing a wound care treatment.<\/span><\/span><\/h1>\n[\/vc_column_text][vc_column_text css=”” animation=”animation bottom-to-top”]\n

LightOx\u2019s LXD231 light-activated treatment causes the destruction of bacteria that commonly colonise wounds through a simple gel product that is activated with light. These gels are simple to apply and can be applied directly to the wound site. LXD231 is capable of both reducing wound-colonising microbes and inhibiting the growth of bacterial biofilms, a common complication of infected wounds, to aid effective wound healing. <\/strong><\/p>\n[\/vc_column_text][vc_empty_space height=”2vh”]\t\n\t\tLearn More<\/span>\n\t\t\t<\/a>\n\t\t[vc_empty_space height=”6vh”][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row thb_full_width=”true” thb_row_padding=”true” thb_column_padding=”true” content_placement=”top” css=”.vc_custom_1625225681279{padding-top: 3vh !important;background-color: #ffffff !important;}” thb_divider_color=”#ffffff” thb_divider_height=”100″ el_class=”align-center” el_id=”LXD191″][vc_column el_class=”align-center” offset=”vc_col-lg-9″][vc_row_inner][vc_column_inner][vc_empty_space height=”8vh”][vc_column_text css=”” animation=”animation bottom-to-top”]\n

\n
LXD231<\/span>
\n<\/strong><\/h6>\n<\/div>\n[\/vc_column_text][vc_empty_space height=”2vh”][vc_column_text css=”” animation=”animation bottom-to-top”]\n

Infections in wounds delay healing and increase the risk of complications such as <\/span>anti-microbial resistance (AMR), gangrene and can necessitate amputation.<\/span><\/h2>\n[\/vc_column_text][vc_empty_space height=”2vh”][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner css=”.vc_custom_1625227432419{padding-right: 3vw !important;}”][vc_column_text css=”” animation=”animation bottom-to-top”]\n
LightOx have developed novel molecules that, when activated by light, generate cytotoxic reactive oxygen species (ROS) that destroy bacteria. We have demonstrated that our lead molecule, LXD231, displays antimicrobial activity against ESKAPE pathogens \u2013 the World Health Organisation\u2019s \u201cpriority\u201d pathogens that exhibit resistance to antibiotics. Antibiotic-resistant bacteria are becoming increasingly prevalent around the world, with the potential to cause ten million deaths per annum by 2050. Bacteria are unable to develop resistance towards ROS generated by LXD231 and, therefore, our treatments can help fight anti-microbial resistance (AMR).<\/h5>\n[\/vc_column_text][vc_empty_space height=”2vh”][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row thb_full_width=”true” thb_row_padding=”true” thb_column_padding=”true” css=”.vc_custom_1625239452832{padding-top: 3vh !important;background-color: #ffffff !important;}” thb_divider_color=”#ffffff” thb_divider_height=”100″ el_class=”align-center”][vc_column el_class=”align-center” offset=”vc_col-lg-9″][vc_row_inner][vc_column_inner][vc_text_separator title=””][vc_empty_space height=”3vh”][vc_column_text animation=”animation bottom-to-top”]\n

Our Solution<\/span><\/h3>\n[\/vc_column_text][vc_empty_space height=”3vh”][vc_column_text css=”” animation=”animation bottom-to-top”]\n
Our treatments look to reduce the number of care appointments required to redress wounds by reducing the bacterial burden, which typically shortens the time<\/span> for wound closure.<\/h5>\n
LightOx wound care treatments are light-activated meaning the treatment is difficult for resistance to occur and can be used in conjunction with other antibiotics to accelerate wound closure times.<\/h5>\n
LightOx wound gels are currently in development with the current focus on formulating the drug API into easy to apply gel formats.<\/h5>\n[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner width=”1\/3″ animation=”animation bottom-to-top” css=”.vc_custom_1578785342773{padding-top: 3vh !important;}”][vc_single_image image=”3228″ img_size=”full” alignment=”center” css=””][vc_column_text css=”” animation=”animation bottom-to-top”]\n

Apply<\/b><\/h3>\n[\/vc_column_text][vc_column_text css=”” animation=”animation bottom-to-top”]\n
Apply the gel to the wound area<\/span><\/h5>\n
Drug targets bacterial infections<\/span><\/h5>\n
Drug penetrates & disrupts biofilms<\/span><\/h5>\n[\/vc_column_text][vc_separator][\/vc_column_inner][vc_column_inner width=”1\/3″ animation=”animation bottom-to-top” css=”.vc_custom_1578785355343{padding-top: 3vh !important;}”][vc_single_image image=”3226″ img_size=”full” alignment=”center” css=””][vc_column_text css=”” animation=”animation bottom-to-top”]\n

Treat<\/b><\/h3>\n[\/vc_column_text][vc_column_text css=”” animation=”animation bottom-to-top”]\n
Specific wavelength<\/span>\u00a0light activates within bacteria
\n<\/span><\/h5>\n
Natural mechanism: ROS production leads to bacterial cell death<\/span><\/h5>\n[\/vc_column_text][vc_separator][\/vc_column_inner][vc_column_inner width=”1\/3″ animation=”animation bottom-to-top” css=”.vc_custom_1578785361383{padding-top: 3vh !important;}”][vc_single_image image=”3227″ img_size=”full” alignment=”center” css=””][vc_column_text css=””]\n

Dress<\/b><\/h3>\n[\/vc_column_text][vc_column_text css=”” animation=”animation bottom-to-top”]\n
Dress wound as normal<\/span><\/h5>\n
Repeated treatment as required<\/span><\/h5>\n[\/vc_column_text][vc_separator][\/vc_column_inner][\/vc_row_inner][vc_empty_space height=”15vh”][\/vc_column][\/vc_row][vc_row thb_full_width=”true” thb_row_padding=”true” thb_column_padding=”true” content_placement=”top” css=”.vc_custom_1625494688918{padding-top: 15vh !important;background-color: #edf2f4 !important;}” thb_divider_color=”#ffffff” thb_divider_height=”100″ el_class=”align-center”][vc_column el_class=”align-center” offset=”vc_col-lg-9″][vc_empty_space height=”3vh”][vc_row_inner][vc_column_inner][vc_column_text css=”” animation=”animation bottom-to-top”]\n

The management of wounds is a <\/span>\u201csilent epidemic\u201d <\/span><\/span>that is challenging health services worldwide.<\/span><\/span>
\n<\/span><\/h2>\n[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_empty_space height=”3vh”][vc_row_inner][vc_column_inner][vc_empty_space height=”3vh”][vc_column_text css=”” animation=”animation bottom-to-top”]\n
In the UK alone the NHS treats around 3.8 million patients with a wound annually, translating to a burden of over \u00a38.3billion<\/span>,<\/a>\u00a0a 48% increase in real terms since 2013<\/h5>\n
The cost of an unhealed wound (\u00a33,700) was approximately 2.5 times more<\/span> than that of a wound that healed during the study period (\u00a31,500)<\/h5>\n
\u201cAn increase in wounds in younger patients is likely to be related to an increase in the prevalence of comorbidities in a younger population<\/span>, as chronic wounds are usually due to comorbidities that affect wound healing, such as patients with diabetes, arterial disease and venous disease\u201d \u2013 UK Government response to House of Lords (HL11875)) (House of Lords Hansard, 2021)<\/h5>\n[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_empty_space height=”3vh”][vc_row_inner][vc_column_inner width=”1\/2″][vc_column_text css=”.vc_custom_1725532638812{padding-right: 2vw !important;}”]LightOx is developing wound-sterilising modalities that:<\/strong><\/p>\n
    \n
  1. Reduces bacterial burden, translating to better healing<\/span> outcomes..<\/li>\n
  2. Remain effective<\/span> against multidrug-resistant bacteria.<\/li>\n
  3. Simple<\/span> to apply and activate.<\/li>\n<\/ol>\n

    This will benefit:<\/strong><\/p>\n

      \n
    1. Patients<\/span> with non-healing chronic wounds.<\/li>\n
    2. Community-care nurses<\/span> with increasing caseloads from non-healing wounds.<\/li>\n
    3. Health services<\/span> by reducing wound care spend-per-patient.<\/li>\n
    4. Reduce antibiotic use; limit<\/span> emergence of multidrug-resistant bacteria<\/span>.<\/li>\n<\/ol>\n[\/vc_column_text][\/vc_column_inner][vc_column_inner width=”1\/2″][vc_column_text css=””]Infection caused by colonising microbes is a major factor that influences the time for the healing of a wound. Untreated infections extend healing times and can spread further necessitating surgery and even amputation.<\/p>\n

      The increasing prevalence of contributing factors such as diabetes and obesity, and the alarming emergence of anti-microbial resistant bacteria (AMR) means the number of resistant infected wounds is rising in all geographies and age groups.<\/p>\n

      With the prospect of a world where antibiotics are no longer effective, we urgently need new modalities, treatments and drugs that can lower bioburden in wounds that aid healing and reduce the financial burden faced by healthcare services.[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_empty_space height=”1vh”][vc_column_text css=”” animation=”animation bottom-to-top”]\n

      With <\/span><\/span>clinical trials planned in the coming months <\/span><\/span>we look for partners, collaborators and investors to support this work alongside those with an active interest in AMR solutions.<\/span><\/span><\/h3>\n[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_empty_space height=”8vh”][vc_row_inner][vc_column_inner el_class=”text-center”][vc_column_text animation=”animation bottom-to-top”]\n

      Get in touch to start a conversation with our team<\/span><\/h3>\n[\/vc_column_text][vc_empty_space height=”1vh”]\t\n\t\tCONTACT<\/span>\n\t\t\t<\/a>\n\t\t[vc_empty_space height=”15vh”][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row thb_full_width=”true” thb_row_padding=”true” thb_column_padding=”true” content_placement=”middle”][vc_column thb_color=”thb-light-column” width=”1\/2″ el_class=”text-center” css=”.vc_custom_1579183788608{padding-top: 25% !important;padding-right: 5% !important;padding-bottom: 25% !important;padding-left: 5% !important;background-image: url(https:\/\/lightox.co.uk\/wp-content\/uploads\/2020\/01\/LIGHTOX_HOME.jpg?id=1335) !important;background-position: center !important;background-repeat: no-repeat !important;background-size: cover !important;}”][vc_column_text animation=”animation bottom-to-top”]\n
      \n
      LIGHTOX<\/span>
      \n<\/strong><\/h6>\n<\/div>\n[\/vc_column_text]\t
      \n\t\t\n

      About<\/span><\/span><\/h1>\n\t\t\t\t